Collegium Pharmaceutical Q3 net income falls 31% to $21.76 million
Bitget2026/11/05 12:44- Collegium Pharmaceutical’s third-quarter 2026 GAAP net income fell 31% year-over-year to $21.8 million.
- Quarterly net revenues rose to $216.3 million.
- JORNAY PM net revenues climbed 24% year-over-year to $51.9 million, while pain portfolio net revenues dropped 18% to $138 million.
- The $50 million accelerated share repurchase program is expected to settle in the fourth quarter of 2026.
- Full-year 2026 net revenues guidance was reaffirmed at $825 million to $855 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The “outlier” in the AI capital expenditure frenzy: Apple (AAPL.US) keeps spending flat, accounting for less than 5% of sales
Apple continues to stand out among major tech peers, largely avoiding the aggressive wave of capital expenditure associated with artificial intelligence (AI) infrastructure.
Youth Employment Declines for 48 Consecutive Months: Behind the Semiconductor Boom, Young South Koreans Are Being Left Behind by the Times
In South Korea, the unemployment rate in October fell to a three-year low of 2.5%. However, the number of employed people decreased by 50,000, youth employment has declined for 48 consecutive months, and domestic demand remains weak.
Strategy (MSTR.US) Faces Potential Removal from MSCI Index, Passive Funds May Sell $2.8 Billion
MicroStrategy is expected to be removed from the MSCI Global Investable Market Index. JPMorgan estimates that passive funds may sell about $2.8 billion worth of shares, and if removed from multiple indexes simultaneously, the scale could reach up to $8.8 billion. Additionally, with BTC falling below its average cost of $75,456, the company’s stock price and financing capacity are under dual pressure.
Crypto prices
More
